KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $15.0 billion.

  • Teva Pharmaceutical Industries' Non-Current Debt fell 634.92% to $15.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.0 billion, marking a year-over-year decrease of 634.92%. This contributed to the annual value of $15.0 billion for FY2025, which is 634.92% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Non-Current Debt stood at $15.0 billion for Q4 2025, which was down 634.92% from $16.8 billion recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Non-Current Debt peaked at $22.3 billion during Q1 2021, and registered a low of $15.0 billion during Q4 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Non-Current Debt value was $18.5 billion (recorded in 2022), while the average stood at $18.5 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Non-Current Debt plummeted by 1568.03% in 2024 and then soared by 223.17% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Non-Current Debt stood at $21.6 billion in 2021, then dropped by 11.63% to $19.1 billion in 2022, then dropped by 4.93% to $18.2 billion in 2023, then decreased by 11.89% to $16.0 billion in 2024, then fell by 6.35% to $15.0 billion in 2025.
  • Its Non-Current Debt stands at $15.0 billion for Q4 2025, versus $16.8 billion for Q3 2025 and $16.8 billion for Q2 2025.